SCHEMBL24882016

SCHEMBL24882016

CN(CCCCN)Cc1ccc(NC(=O)CCCCCCC(=O)OC(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 5/20 0.53
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
HDAC1 Q13547 3/20 0.44
HDAC6 Q9UBN7 3/20 0.44
HDAC3 O15379 3/20 0.44
HDAC4 P56524 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
LTA4H P09960 6/20 0.43
GPR4 P46093 1/20 0.43
ESR1 P03372 1/20 0.43
NCOR2 Q9Y618 1/20 0.42
BCHE P06276 2/20 0.42
ACHE P22303 2/20 0.42
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24881881 0.85 TMEM97 (0.53) HDAC8TMEM97SIGMAR1HDAC1HDAC6
SCHEMBL29908938 0.82 KMT2A (0.57) TMEM97SIGMAR1ACHE
SCHEMBL29908969 0.81 HDAC8 (0.57) HDAC8TMEM97SIGMAR1HDAC1HDAC6
SCHEMBL24880999 0.76 HDAC8 (0.61) HDAC8HDAC1HDAC6HDAC3HDAC4
SCHEMBL29908950 0.76 HDAC8 (0.51) HDAC8HDAC1HDAC6HDAC3HDAC4
SCHEMBL24881075 0.76 HDAC8 (0.63) HDAC8HDAC1HDAC6HDAC3HDAC4
SCHEMBL31522340 0.76 HDAC8 (0.67) HDAC8HDAC1HDAC6HDAC3HDAC4
SCHEMBL29908941 0.75 HDAC8 (0.50) HDAC8TMEM97SIGMAR1HDAC1HDAC6
SCHEMBL29714948 0.75 HDAC8 (0.59) HDAC8HDAC1HDAC6HDAC3HDAC4
SCHEMBL29908940 0.74 HDAC8 (0.56) HDAC8HDAC1HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569563-B2 Selective HDAC6 degraders and methods of use thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-03-10 US disclosed
US-20230011665-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-12 US disclosed
US-20230011665-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-12 US disclosed
EP-4054607-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2022-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011665-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF HDAC6, HDAC1, HDAC11 HDAC8 8/4885TMEM97 4209/4885SIGMAR1 3805/4885
US-12569563-B2 Selective HDAC6 degraders and methods of use thereof HDAC6, HDAC1, HDAC11 HDAC8 9/4885TMEM97 2553/4885SIGMAR1 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.